Healthcare Losers: Cytokinetics (NASDAQ:CYTK), Achillion Pharmaceuticals (NASDAQ:ACHN), Pharmacyclics (NASDAQ:PCYC), Organovo Holdings Inc (NYSEMKT:ONVO)

Cytokinetics, Inc. (NASDAQ:CYTK) announced disappointing top-line results from its BENEFIT-ALS midstage study involving tirasemtiv. Tirasemtiv did not meet its primary efficacy endpoint of delivering a mean change from baseline in the ALS functional rating scale. Cytokinetics, Inc. (NASDAQ:CYTK) stock performance was -64.67% in last session and finished the day at $4.59. Traded volume was 17.26million shares in the last session and the average volume of the stock remained 1.05million shares. The beta of the stock remained 1.51. Cytokinetics, Inc. (NASDAQ:CYTK) insider ownership is 25.04%.

Achillion Pharmaceuticals Inc (NASDAQ:ACHN) holds the promise of developing an all-oral HCV regimen that can be competitive in the evolving HCV treatment landscape. It is the only small-cap biotech company with HCV drug candidates in three key classes – NS5A, nucleotide NS5B polymerase and protease inhibitors. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) dropped -6.19 percent to $2.73 Friday on volume of 1.22million shares. The intra-day range of the stock was $2.68 to $2.96. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has a market capitalization of $264.25million.

Investors in Pharmacyclics, Inc. (NASDAQ:PCYC) saw new options become available, for the June 6th expiration. Analyst has looked up and down the PCYC options chain for the new June 6th contracts and identified one put and one call contract of particular interest. Pharmacyclics, Inc. (NASDAQ:PCYC)’s stock on Apr 25, 2014 reported a decrease of -6.12% to the closing price of $88.70. Its fifty two weeks range is $74.36 -$154.89. The total market capitalization recorded $6.65billion. The overall volume in the last trading session was 1.71million shares. In its share capital, PCYC has 75.02million outstanding shares.

Organovo Holdings Inc (NYSEMKTS:ONVO) has filed a lawsuit against Simeon Research, a firm which has issued a couple of scathing reports against the 3D bio-printing company. On Friday, shares of Organovo Holdings Inc (NYSEMKT:ONVO) dropped -9.17% to close the day at $5.55. Company return on investment (ROI) is -44.40% and its monthly performance is recorded as -31.65%. Organovo Holdings Inc (NYSEMKT:ONVO) quarterly revenue growth is -39.14%.